文献速递胸部肿瘤放疗姑息放疗与转移瘤

质子心脏保护加速分次放疗联合延长度伐利尤单抗治疗不可切除非小细胞肺癌的试验性研究(PARTICLE-D)

A Pilot Trial of Proton-Based Cardiac Sparing Accelerated Fractionated Radiation Therapy in Unresectable Non-small Cell Lung Cancer With Extended Durvalumab Therapy (PARTICLE-D).
PubMed 文献 · Pract Radiat Oncol · 2024-07-14

这项1期试验性剂量递增研究纳入7例无法或不接受同步放化疗的IIIA-IIIC期非小细胞肺癌患者,接受度伐利尤单抗联合大分割质子外照射放疗。所有患者出现治疗相关不良事件,主要为1-2级;1例剂量限制性毒性为3级肺炎导致5级肺炎,另有2例治疗开始后>13个月发生迟发性5级气管坏死,共3例治疗相关死亡。作者认为需进行质子放疗联合度伐利尤单抗的剂量降阶梯方案。

要点

  • 7例患者接受度伐利尤单抗联合大分割质子放疗,所有患者出现治疗相关不良事件,主要为1-2级。
  • 1例剂量限制性毒性为3级肺炎导致5级肺炎,另2例迟发性5级气管坏死发生于治疗开始后>13个月。
  • 共3例治疗相关死亡影响总体安全性,作者认为需进行剂量降阶梯方案。

核心结论

  • 同步度伐利尤单抗联合大分割质子外照射放疗短期耐受性良好,但3例治疗相关死亡(包括2例迟发性5级气管坏死)对总体安全性产生负面影响。
  • 作者认为需进行质子放疗联合度伐利尤单抗的剂量降阶梯方案。

研究设计与样本

  • 1期试验性剂量递增研究,采用3+3设计,纳入7例新诊断IIIA至IIIC期非小细胞肺癌且无法或不接受同步放化疗的患者,排除既往接受免疫治疗者。
  • 5例患者接受60 Gy/20次(Arm 1),2例患者接受69 Gy/23次(Arm 2),均联合每28天周期第1天固定剂量度伐利尤单抗。
  • 主要目标为评估安全性,次要目标为评估可行性和不良事件。

主要发现

  • 所有患者出现治疗相关不良事件,主要为1级和2级,肺炎和贫血最常见。
  • Arm 1发生1例剂量限制性毒性,为3级肺炎导致5级肺炎。
  • 2例迟发性5级气管坏死事件发生于治疗开始后>13个月。
  • 共3例治疗相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Concurrent chemoradiation therapy is the current nonsurgical standard of care for locally advanced non-small cell lung cancer. However, this is a difficult regimen to tolerate, especially for those who are elderly, have multiple comorbidities, or have poor performance status. Alternative treatment regimens are needed for this vulnerable population. We report initial results of concurrent durvalumab, an immune checkpoint inhibitor, and hypofractionated, dose-escalating, proton external beam radiation therapy (EBRT). METHODS AND MATERIALS: This phase 1, pilot dose escalation trial enrolled 7 patients with newly diagnosed stage IIIA to IIIC non-small cell lung cancer and who were unable or unwilling to undergo concurrent chemoradiation therapy. Patients previously treated with immunotherapy were excluded. Five patients in this 3 + 3 study design received a fixed dose of durvalumab on day 1 of each 28-day cycle plus hypofractionated proton EBRT with initial dose of 60 Gy (Arm 1) in 20 fractions while 2 patients received the escalation dose of 69 Gy in 23 fractions (Arm 2). The primary objective was to assess safety and the secondary objective was to assess feasibility and adverse events. RESULTS: All patients experienced treatment-related adverse events, primarily grades 1 and 2. Pneumonitis and anemia were the most common. Only 1 dose-limiting toxicity occurred in arm 1, which was a grade 3 pneumonitis leading to grade 5 pneumonia. Additionally, 2 delayed-onset grade 5 tracheal necrosis events occurred >13 months after treatment initiation. CONCLUSIONS: Concurrent durvalumab plus hypofractionated proton EBRT was well tolerated in the short term. However, 3 treatment-related deaths, including 2 delayed-onset grade 5 tracheal necroses negatively impacted overall safety. A dose de-escalation protocol of proton-based radiation therapy plus durvalumab is warranted.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bruno DS, Mitchell C, Dowlati A, et al. A Pilot Trial of Proton-Based Cardiac Sparing Accelerated Fractionated Radiation Therapy in Unresectable Non-small Cell Lung Cancer With Extended Durvalumab Therapy (PARTICLE-D). Pract Radiat Oncol. 2024. PMID: 39002856. doi:10.1016/j.prro.2024.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。